Changing Landscape of Systemic Therapy in Biliary Tract Cancer.
FGFR2
HER2
IDH
NTRK
cholangiocarcinoma
durvalumab
gall bladder cancer
gemcitabine
infrigatinib
pemigatinib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Apr 2022
25 Apr 2022
Historique:
received:
28
03
2022
revised:
17
04
2022
accepted:
22
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Biliary tract cancers (BTC) are often diagnosed at advanced stages and have a grave outcome due to limited systemic options. Gemcitabine and cisplatin combination (GC) has been the first-line standard for more than a decade. Second-line chemotherapy (CT) options are limited. Targeted therapy or TT (fibroblast growth factor 2 inhibitors or FGFR2, isocitrate dehydrogenase 1 or IDH-1, and neurotrophic tyrosine receptor kinase or NTRK gene fusions inhibitors) have had reasonable success, but <5% of total BTC patients are eligible for them. The use of immune checkpoint inhibitors (ICI) such as pembrolizumab is restricted to microsatellite instability high (MSI-H) patients in the first line. The success of the TOPAZ-1 trial (GC plus durvalumab) is promising, with numerous trials underway that might soon bring targeted therapy (pemigatinib and infrigatinib) and ICI combinations (with CT or TT in microsatellite stable cancers) in the first line. Newer targets and newer agents for established targets are being investigated, and this may change the BTC management landscape in the coming years from traditional CT to individualized therapy (TT) or ICI-centered combinations. The latter group may occupy major space in BTC management due to the paucity of targetable mutations and a greater toxicity profile.
Identifiants
pubmed: 35565266
pii: cancers14092137
doi: 10.3390/cancers14092137
pmc: PMC9105885
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Ann Surg Oncol. 2016 Sep;23(9):2998-3008
pubmed: 27169772
Oncologist. 2023 Jul 5;28(7):e520-e525
pubmed: 36994874
J Natl Cancer Inst. 1997 Aug 6;89(15):1132-8
pubmed: 9262251
FASEB J. 1995 Mar;9(5):313-23
pubmed: 7896000
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Am J Surg. 1997 Dec;174(6):605-8; discussion 608-9
pubmed: 9409582
Nat Rev Cancer. 2003 Jan;3(1):35-45
pubmed: 12509765
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Front Oncol. 2021 Apr 12;11:646979
pubmed: 33912461
Br J Surg. 2018 Feb;105(3):192-202
pubmed: 29405274
Clin Cancer Res. 2019 May 1;25(9):2699-2707
pubmed: 30745300
JAMA Oncol. 2018 Nov 1;4(11):1569-1575
pubmed: 30098152
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-20
pubmed: 33989023
Cancer Res. 2010 Dec 15;70(24):10288-98
pubmed: 21159648
J Clin Oncol. 2016 Jan 20;34(3):219-26
pubmed: 26503201
Clin Gastroenterol Hepatol. 2013 Jan;11(1):13-21.e1; quiz e3-4
pubmed: 22982100
Clin Cancer Res. 2018 Mar 15;24(6):1277-1286
pubmed: 29138340
Hepatology. 2014 Apr;59(4):1427-34
pubmed: 24122810
Oncol Lett. 2020 Aug;20(2):1001-1014
pubmed: 32724339
Nat Rev Drug Discov. 2009 Mar;8(3):235-53
pubmed: 19247306
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Ann Surg. 2007 May;245(5):755-62
pubmed: 17457168
BMC Cancer. 2016 Feb 24;16:153
pubmed: 26912134
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461347
Hepatology. 2001 Jun;33(6):1353-7
pubmed: 11391522
Br J Cancer. 2008 Jan 29;98(2):418-25
pubmed: 18087285
Pharmaceuticals (Basel). 2017 Jan 05;10(1):
pubmed: 28067771
Med Oncol. 2020 Jun 11;37(7):61
pubmed: 32529264
J Clin Oncol. 2011 Dec 10;29(35):4627-32
pubmed: 22067404
Anticancer Res. 2005 Sep-Oct;25(5):3575-9
pubmed: 16101182
World J Hepatol. 2015 Oct 8;7(22):2396-403
pubmed: 26464755
Int J Cancer. 2018 Jul 15;143(2):438-448
pubmed: 29451302
Curr Cancer Drug Targets. 2009 May;9(3):419-38
pubmed: 19442060
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
J Clin Invest. 2021 Dec 15;131(24):
pubmed: 34907910
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
J Clin Oncol. 2019 Apr 20;37(12):1015-1027
pubmed: 30856044
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):295-308
pubmed: 25966429
Oncologist. 2019 Aug;24(8):e702-e708
pubmed: 30902918
Clin Cancer Res. 2013 Apr 15;19(8):2224-31
pubmed: 23479678
J Hepatol. 2004 Mar;40(3):472-7
pubmed: 15123362
Br J Cancer. 2020 Mar;122(5):634-639
pubmed: 31919404
Radiother Oncol. 2011 May;99(2):120-3
pubmed: 21621289
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Clin Cancer Res. 2022 Jun 1;28(11):2229-2236
pubmed: 35312753
J Clin Oncol. 2016 Feb 10;34(5):460-8
pubmed: 26668346
Int Immunopharmacol. 2020 Dec;89(Pt B):107069
pubmed: 33242709
Ther Adv Med Oncol. 2021 Aug 07;13:17588359211035983
pubmed: 34394748
Sci Rep. 2021 Mar 18;11(1):6276
pubmed: 33737613
Cancer. 2021 Jul 1;127(13):2238-2250
pubmed: 33748947
Front Oncol. 2013 Jul 02;3:169
pubmed: 23847760
Lancet Oncol. 2021 Sep;22(9):1290-1300
pubmed: 34339623
Cancer Treat Rev. 2016 May;46:51-62
pubmed: 27109926
J Clin Oncol. 2022 Jan 20;40(3):262-271
pubmed: 34662180
Cancer Metastasis Rev. 2017 Mar;36(1):141-157
pubmed: 27981460
Cancer. 2021 Nov 1;127(21):3975-3984
pubmed: 34355801
Ann Oncol. 2020 Oct;31(10):1405-1412
pubmed: 32622884
Clin Cancer Res. 2020 Dec 1;26(23):6158-6167
pubmed: 32878766
J Hematol Oncol. 2017 Jan 5;10(1):4
pubmed: 28057014
Front Oncol. 2021 Nov 15;11:768009
pubmed: 34868996
Exp Mol Med. 2017 Sep 8;49(9):e375
pubmed: 28883547
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217756
Pharmacol Ther. 2017 Nov;179:171-187
pubmed: 28564583
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
J Hepatobiliary Pancreat Sci. 2014 May;21(5):301-8
pubmed: 24408775
Cancer Treat Res Commun. 2021;27:100354
pubmed: 33756174
Ann Oncol. 2007 Jun;18(6):977-84
pubmed: 17229773
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
JAMA Oncol. 2019 Jun 01;5(6):824-830
pubmed: 30998813
Gan To Kagaku Ryoho. 2014 Nov;41(12):2083-5
pubmed: 25731430
Br J Cancer. 2009 Aug 18;101(4):621-7
pubmed: 19672264
JAMA Oncol. 2020 Jun 1;6(6):888-894
pubmed: 32352498
Cancer. 1995 Nov 15;76(10):1747-56
pubmed: 8625043
JCO Precis Oncol. 2019 Oct 17;3:
pubmed: 32923849
J Transl Med. 2014 Mar 07;12:61
pubmed: 24606884
Medicine (Baltimore). 2020 Aug 7;99(32):e21457
pubmed: 32769873
Cancer Control. 2017 Jul-Sep;24(3):1073274817729245
pubmed: 28975830
Eur J Cancer. 2022 Mar;164:80-87
pubmed: 35182925
Breast Care (Basel). 2013 Mar;8(1):49-55
pubmed: 24715843
Cancer. 2020 Jun 1;126(11):2666-2678
pubmed: 32129902
JAMA Surg. 2014 Jun;149(6):565-74
pubmed: 24718873
J Hepatobiliary Pancreat Sci. 2023 Jan;30(1):102-110
pubmed: 35900311
Eur J Surg Oncol. 2003 Dec;29(10):879-83
pubmed: 14624781
J Clin Oncol. 2020 Nov 20;38(33):3895-3904
pubmed: 32758030
Br J Surg. 2018 Jun;105(7):839-847
pubmed: 28858392
J Clin Oncol. 2019 Mar 10;37(8):658-667
pubmed: 30707660
Target Oncol. 2022 Sep;17(5):517-527
pubmed: 36114955
Thyroid. 2018 Nov;28(11):1455-1461
pubmed: 30142994
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Ann Oncol. 2017 Oct 01;28(10):2377-2385
pubmed: 28945858
Cancer. 2016 Dec 15;122(24):3838-3847
pubmed: 27622582
Ann Oncol. 2018 Jul 1;29(7):1561-1568
pubmed: 29726923
Front Oncol. 2020 Jun 18;10:893
pubmed: 32626654
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493
Lancet Oncol. 2020 Sep;21(9):1234-1243
pubmed: 32818466
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Breast Cancer (Dove Med Press). 2015 Jun 09;7:147-62
pubmed: 26089701
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
Future Oncol. 2020 Oct;16(30):2375-2384
pubmed: 32580579
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815
pubmed: 34358484
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):148-53
pubmed: 18805651
Int J Mol Sci. 2019 Sep 07;20(18):
pubmed: 31500224
Front Oncol. 2021 Mar 03;11:657868
pubmed: 33763382
J Egypt Natl Canc Inst. 2016 Mar;28(1):1-6
pubmed: 26265290
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463
Invest New Drugs. 2022 Feb;40(1):134-141
pubmed: 34463891
Visc Med. 2021 Feb;37(1):32-38
pubmed: 33708816
Curr Oncol. 2018 Oct;25(5):e403-e410
pubmed: 30464691
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Cancer Treat Rev. 2021 Apr;95:102170
pubmed: 33735689
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Ann Surg Oncol. 2013 Jan;20(1):318-24
pubmed: 23149849
Liver Int. 2019 May;39 Suppl 1:98-107
pubmed: 30831002
Lancet Oncol. 2021 Nov;22(11):1560-1572
pubmed: 34656226